The next round of the generic drug user fee program will tie industry fees to approved abbreviated new drug applications as opposed to requiring industry to pay fees when an application is submitted regardless of whether it is approved, FDA said Friday (Oct. 21). FDA also announced the fee will be charged in three tiers rather than a per-ANDA basis, in an effort to align fee responsibility with costs and ability to pay. “We think this is important not only...